{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-004017","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2023-03-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.581334+00:00","generated_at":"2026-06-18T01:30:25.636961+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Armata reports Q4 2022 loss of $10.3M; positive phage trial data, $30M financing closed","bullets":["R&D expenses $9.6M in Q4 2022, up from $4.8M in Q4 2021, driven by clinical trial investment.","Cash $14.9M at Dec 31, 2022; closed $30M convertible credit with Innoviva in Q4.","Positive topline results from SWARM-P.a. Phase 1b/2a for AP-PA02 in CF patients; advancing to Phase 2b.","First patient dosed in Phase 2 NCFB study for AP-PA02; AP-SA02 bacteremia study first cohort completed.","Loss from operations $(10.3)M vs $(6.0)M in Q4 2021; grant revenue $1.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-004017","json":"https://secwatch.observer/filing/0001558370-23-004017.json","markdown":"https://secwatch.observer/filing/0001558370-23-004017.md","text":"https://secwatch.observer/filing/0001558370-23-004017.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000155837023004017/0001558370-23-004017-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000155837023004017/armp-20230316x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T01:30:25.636961+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"708880c5478575e3e1c8f4bc823baf2a3fd89b55","claim":"Armata Pharmaceuticals, Inc. reported financial results for full fiscal year ended December 31, 2022.","evidence_excerpt":"Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2022 Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000155837023004017/0001558370-23-004017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full fiscal year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"83a7bb46e95401c426cdd09bb9808d38f14328fc","claim":"Armata Pharmaceuticals, Inc. reported three months ended December 31, 2022 results: revenue approximately $1.1 million.","evidence_excerpt":"team is well-positioned for a successful 2023,” concluded Dr. Varnum. Fourth Quarter 2022 Financial Results Grant Revenue. The Company recognized grant revenue of approximately $1.1 million for the three months ended December 31, 2022, which represents Medical Technology Enterprise Consortium (“MTEC”)’s share of the costs incurred for the Company’s AP-SA02 program","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000155837023004017/0001558370-23-004017-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended December 31, 2022"},{"label":"Revenue","value":"approximately $1.1 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}